Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-07-19

FDA Approved: AKLIEF — Supplemental Application (Galderma Laboratories, L.P.)

View source ↗

Summary

This FDA document concerns a supplemental application for AKLIEF (trifarotene) submitted by Galderma Laboratories, L.P.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AKLIEF (trifarotene)

Snippet

SUPPL AP for AKLIEF (TRIFAROTENE)